Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Agenus reported that 25% of recurrent ovarian cancer patients treated with BOT+BAL were alive and off all therapy at the last follow-up, with an estimated three-year survival rate of 48% among evaluable patients. The survival estimate remained consistent at 48% between the second and third years, indicating a durable benefit. The results were observed in a heavily pretreated population, with a median of four prior lines of therapy, and nearly 75% of patients had platinum-resistant or refractory cancer.